UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																	
1. Name and Address of Reporting Person* WEISS MICHAEL S					2. Issuer Name and Ticker or Trading Symbol Fortress Biotech, Inc. [FBIO]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director _X_ 10% Owner						
(Last) (First) (Middle) C/O FORTRESS BIOTECH, INC., 2 GANSEVOORT STREET, 9TH FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 01/01/2020								X Officer (give title below) Other (specify below) EXECUTIVE VICE CHAIRMAN						
NEW YORK, NY 10014				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _ Form filed by More than One Reporting Person							
(City		(State)	(Zip)			T:	hle I	- Nor	ı-Der	ivative	Secui	rities	Acan	ired Disn	osed of or I	Beneficially	Owned		
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	Exec		eemed tion Date, if	(Instr. 8)				ired 5. Amou Beneficia Reported		ant of Securities ally Owned Following d Transaction(s)		6. Owner Form:	7. ship of Be	7. Nature of Indirect Beneficial		
				(Mon	nth/Day/	Year)		ode	V	Amou		(A) or (D)	Price	(Instr. 3 a	and 4)		Direct or Indi (I) (Instr.	rect (In	wnership nstr. 4)
Common Stock		01/01/2020				A			801,53	36 _A	A	\$ 0	10,201,811			D			
								quire	the f	orm dis	splay of, or	ys a c	curre eficial		OMB conf	spond unle trol numbe			
		I			outs, call	ls, wa		ts, op							I	I			
Security	2. Conversion or Exercise Price of Derivative Security	3. Transactio Date (Month/Day/	Execution Day	Transaction Code Year) (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ow For Der Sec Dir or I (s) (I)	nership m of	Beneficia Ownersh (Instr. 4)		
					Code	V	(A)	(D)	Date Exer	cisable		ration	Title	Amount or Number of Shares					
Repor	ting O	wners																	

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
WEISS MICHAEL S C/O FORTRESS BIOTECH, INC. 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014	X	X	EXECUTIVE VICE CHAIRMAN					

Signatures

/s/ Samuel Berry / Attorney-in-Fact	03/13/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) The Reporting Person was granted 801,536 restricted shares pursuant to the Issuer's Long Term Incentive Plan on January 1, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.